ISAB: Record order backlog and FDA validation drive growth plans despite widening losses

About this update from Inhalation Sciences Sweden Ab

Order backlog hit 45 MSEK after new FDA guidelines, but Q1 sales fell and losses widened. A 15.2 MSEK rights issue is planned to fund commercialization, with break-even targeted at 13 MSEK annual sales. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Inhalation Sciences Sweden Ab